Journal of International Psychiatry

[Abstract] Objective: To explore the impact of using selenide therapy on the psychological, emotional, and mental states of patients with tumor associated depression. Method: Case data were collected from March 2022 to March 2023 and included in the file. The subjects were 96 patients with tumors and depression admitted to the hospital. The subjects were divided into a control group and an observation group based on the "random number table" method, and were treated with amitriptyline and selenide, with 48 cases in each group; Observe and compare the degree of depression, mental state, sleep quality, and quality of life between the two groups. Result: After treatment, the scores of the Self Rating Anxiety Scale (SAS) and Self Rating Depression Scale (SDS) in both groups decreased to varying degrees, and the observed group showed a greater decrease than the control group (P<0.05); After treatment, the symptom checklist 90 (SCL-90) scores of both groups significantly decreased, and the observation group was lower than the control group (P<0.05); After treatment, the Pittsburgh Sleep Quality Index (PSQI) score in the observation group was significantly lower than that in the control group (P<0.05); After treatment, the EORTC QLQ-C30 score of cancer patients in the observation group was better than that in the control group (P<0.05). Conclusion: The treatment of cancer patients with depression using selenide can effectively improve their depressive state, improve sleep quality, and achieve a good prognosis.

[Keywords] Selete; Tumor patients; Depression; Clinical effects